Abstract
The polypeptide component of telomerase (TERT) is an attractive candidate for a broadly expressed tumor rejection antigen because telomerase is silent in normal tissues but is reactivated in more than 85% of cancers. Here we show that immunization against TERT induces immunity against tumors of unrelated origin. Immunization of mice with TERT RNA-transfected dendritic cells (DC) stimulated cytotoxic T lymphocytes (CTL), which lysed melanoma and thymoma tumor cells and inhibited the growth of three unrelated tumors in mice of distinct genetic backgrounds. TERT RNA-transfected human DC stimulated TERT-specific CTL in vitro that lysed human tumor cells, including Epstein Barr virus (EBV)-transformed B cells as well as autologous tumor targets from patients with renal and prostate cancer. Tumor RNA-transfected DC were used as surrogate targets in the CTL assays, obviating the difficulties in obtaining tumor cells from cancer patients. In one instance, where a tumor cell line was successfully established in culture from a patient with renal cancer, the patient's tumor cells were efficiently lysed by the CTL. Immunization with tumor RNA was generally more effective than immunization with TERT RNA, suggesting that an optimal immunization protocol may have to include TERT as well as additional tumor antigens.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Rosenberg, S.A. A new era for cancer immunotherapy based on the genes that encode cancer antigens . Immunity 10, 281–287 (1999).
Boon, T. & van der Bruggen, P. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183, 725– 729 (1996).
Blackburn, E.H. Structure and function of telomeres. Nature 350, 569–573 (1991).
Greider, C.W. Telomere length regulation. Annu. Rev. Biochem. 65, 337–365 (1996).
Hodes, R.J. Telomere length, aging, and somatic cell turnover. J. Exp. Med. 190, 153–156 ( 1999).
Weng, N.P., Hathcock, K.S. & Hodes, R.J. Regulation of telomere length and telomerase in T and B cells: a mechanism for maintaining replicative potential. Immunity 9, 151–157 ( 1998).
Hiyama, K. et al. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J. Immunol. 155, 3711– 3715 (1995).
Prowse, K.R. & Greider, C.W. Developmental and tissue-specific regulation of mouse telomerase and telomere length. Proc. Natl. Acad. Sci. USA 92, 4818–4822 (1995).
Shay, J.W. & Bacchetti, S. A survey of telomerase activity in human cancer. Eur. J. Cancer 33, 787– 791 (1997).
Kim, N.W. et al. Specific association of human telomerase activity with immortal cells and cancer [see comments]. Science 266, 2011–2015 (1994).
Greenberg, R.A., Allsopp, R.C., Chin, L., Morin, G.B. & DePinho, R.A. Expression of mouse telomerase reverse transcriptase during development, differentiation and proliferation. Oncogene 16, 1723–1730 ( 1998).
Ramakrishnan, S., Eppenberger, U., Mueller, H., Shinkai, Y. & Narayanan, R. Expression profile of the putative catalytic subunit of the telomerase gene. Cancer Res. 58, 622–625 (1998).
Meyerson, M. et al. hEST2, the putative human telomerase catalytic subunit gene, is up- regulated in tumor cells and during immortalization. Cell 90, 785–795 ( 1997).
Kilian, A. et al. Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. Hum. Mol. Genet. 6, 2011–2019 (1997).
Vonderheide, R.H., Hahn, W.C., Schultze, J.L. & Nadler, L.M. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10, 673–679 (1999).
Yewdell, J.W., Norbury, C.C. & Bennink, J.R. Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: implications for generating CD8+ T cell responses to infectious agents, tumors, transplants, and vaccines. Adv. Immunol. 73, 1–77 ( 1999).
Simpson, E., Gordon, R. D. Responsiveness to H-Y antigen: Ir gene complementation and target cell specificity. Immunol. Rev. 35, 59–75 ( 1977).
Ashley, D.M. et al. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors . J. Exp. Med. 186, 1177– 1182 (1997).
Boczkowski, D., Nair, S.K., Snyder, D. & Gilboa, E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 184, 465–472 (1996).
Nair, S.K. et al. Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T- lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA. Int. J. Cancer 82, 121– 124 (1999).
Nair, S.K. et al. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nature Biotechnol. 16, 364– 369 (1998).
Boczkowski, D., Nair, S.K., Nam, J.H., Lyerly, H.K. & Gilboa, E. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res. 60, 1028– 1034 (2000).
Piatyszek, M.A.,. et al. Detection of telomerase activity in human cells and tumors by a telomeric repeat amplification protocol (TRAP). Methods Cell Sci. 17, 1–15 ( 1995).
Yewdell, J.W. & Bennink, J.R. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol. 17, 51–88 ( 1999).
Porgador, A., Feldman, M. & Eisenbach, L. H-2Kb transfection of B16 melanoma cells results in reduced tumourigenicity and metastatic competence. J. Immunogenet. 16, 291–303 ( 1989).
Coveney, E., Clary, B., Iacobucci, M., Philip, R. & Lyerly, K. Active immunotherapy with transiently transfected cytokine-secreting tumor cells inhibits breast cancer metastases in tumor-bearing animals. Surgery 120, 265–272; discussion 272–263 (1996).
Hicklin, D.J., Marincola, F.M. & Ferrone, S. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol. Med. Today 5, 178–186 (1999).
Garrido, F. et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today 18, 89–95 (1997).
Weidt, G., Utermohlen, O., Heukeshoven, J., Lehmann-Grube, F. & Deppert, W. Relationship among immunodominance of single CD8+ T cell epitopes, virus load, and kinetics of primary antiviral CTL response. J. Immunol. 160, 2923– 2931 (1998).
Mylin, L.M., Bonneau, R.H., Lippolis, J.D. & Tevethia, S.S. Hierarchy among multiple H-2b-restricted cytotoxic T-lymphocyte epitopes within simian virus 40 T antigen. J. Virol. 69, 6665–6677 (1995).
Fu, T.M., Friedman, A., Ulmer, J.B., Liu, M.A. & Donnelly, J.J. Protective cellular immunity: cytotoxic T-lymphocyte responses against dominant and recessive epitopes of influenza virus nucleoprotein induced by DNA immunization. J. Virol. 71, 2715–2721 ( 1997).
Chen, Y., Webster, R.G. & Woodland, D.L. Induction of CD8+ T cell responses to dominant and subdominant epitopes and protective immunity to Sendai virus infection by DNA vaccination. J. Immunol. 160, 2425– 2432 (1998).
Oukka, M. et al. Protection against lethal viral infection by vaccination with nonimmunodominant peptides. J. Immunol. 157, 3039–3045 (1996).
Van Waes, C., Monach, P.A., Urban, J.L., Wortzel, R.D. & Schreiber, H. Immunodominance deters the response to other tumor antigens thereby favoring escape: prevention by vaccination with tumor variants selected with cloned cytolytic T cells in vitro. Tissue Antigens 47, 399–407 (1996).
Johnston, J.V. et al. B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes. J. Exp. Med. 183, 791– 800 (1996).
Gilboa, E. The makings of a tumor rejection antigen [In Process Citation]. Immunity 11, 263–270 ( 1999).
Srivastava, P.K. Do human cancers express shared protective antigens? or the necessity of remembrance of things past. Semin. Immunol. 8, 295– 302 (1996).
Moore, M.W., Carbone, F.R. & Bevan, M.J. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 54, 777–785 (1988).
DeKernion, J.B., Soloway, M.S. & Persky, L. Chemotherapy of experimental transitional-cell carcinoma . Urology 4, 63–68 (1974).
Inaba, K. et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176, 1693– 1702 (1992).
Romani, N. et al. Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180, 83–93 (1994).
Volgmann, T., Klein-Struckmeier, A. & Mohr, H. A fluorescence-based assay for quantitation of lymphokine-activated killer cell activity. J. Immunol. Methods 119, 45–51 (1989).
Acknowledgements
The authors wish to thank David Snyder for animal care, Doris Coleman for patient recruitment, Monica Fernandes-Casal and Kristin Keck for generation of murine DC, Alivelu Basara and XuRong Jiang for TERT RT-PCR studies and Judy Hall for technical assistance in the preparation of the manuscript. This study was supported by a generous anonymous gift to the Duke University Cancer Center.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nair, S., Heiser, A., Boczkowski, D. et al. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. . Nat Med 6, 1011–1017 (2000). https://doi.org/10.1038/79519
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/79519
This article is cited by
-
The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II–III and metastatic breast cancers
Breast Cancer Research and Treatment (2022)
-
CD11c+ MHCIIlo GM-CSF-bone marrow-derived dendritic cells act as antigen donor cells and as antigen presenting cells in neoepitope-elicited tumor immunity against a mouse fibrosarcoma
Cancer Immunology, Immunotherapy (2018)
-
A second chance for telomerase reverse transcriptase in anticancer immunotherapy
Nature Reviews Clinical Oncology (2017)
-
Tools for translation: non-viral materials for therapeutic mRNA delivery
Nature Reviews Materials (2017)
-
Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination
Journal of Experimental & Clinical Cancer Research (2016)